Redeye initiates coverage of Klaria Pharma Holding AB, a Swedish biotech company, utilising its transmucoadhesive drug delivery technology platform to offer efficient and reliable treatments. We view the current share price as attractive for a significant long-term upside as we believe Klaria has the potential to provide next-generation drug delivery.